Abstract. Cyclin-dependent kinase inhibitors CDKN2B and CDKN2A are tumor suppressor genes that are frequently dysregulated in a variety of cancers. Aberrant regulation via DNA hypermethylation causes gene silencing. Arsenic trioxide has been successfully used to treat malignant, hematopoietic diseases and is known to act by induction of apoptosis and inhibition of cellular proliferation. However, arsenic trioxide has been recently reported to act via inhibition of DNA hypermethylation in some solid tumors. The goal of this study was to explore the mechanism of arsenic trioxide induced demethylation of the CDKN2B and CDKN2A promoters in the hematologic malignant cell lines Molt4, MUTZ-1, U937, U266 and CA46. We used bisulphate modification and nested-methylation specific PCR to determine the levels of methylated and unmethylated promoter sequences in untreated and As 2 O 3 -treated cells. We used semi-quantitative RT-PCR and immunoblotting to quantify CDKN2B and CDKN2A mRNA and protein levels, respectively. We measured DNMT activity in nuclear extracts of untreated and treated cells using radiolabeled SAM as a methyl donor. The CDKN2B promoter was hypermethylated in Molt4 and MUTZ-1 cells, while the CDKN2A promoter was hypermethylated in U937, U266 and CA46 cells. As 2 O 3 treatment caused demethylation associated with an increase in mRNA levels of the CDKN2B and CDKN2A genes. We also demonstrated a concomitant inhibition in DNMT activity and DNMT mRNA levels in As 2 O 3 -treated cells. In summary, As 2 O 3 restored expression levels of tumor suppressor genes in hematologic malignant cells by causing promoter demethylation along with an inhibition of DNMTs 1, 3a and 3b.
Introduction
Cell cycle progression is a tightly regulated process that governs cell size, genomic integrity and coordination of multiple cellular signaling events (1, 2) . Dysregulation of the cell cycle is the hallmark of tumor development. Cyclindependent kinases and their cyclin partners are important positive regulators accelerating the progression of the cell cycle while the cyclin-dependent kinase inhibitors act as negative regulators. The CDKN2B (p15) and CDKN2A (p16) genes located on chromosome 9p21, are two important cyclindependent kinase inhibitors which are known to be frequently mutated or deleted in a wide variety of cancers (2) . Loss of expression of these genes confers a growth advantage to a number of tumors leading to these genes being classified as candidate tumor suppressor genes. Inactivation of tumor suppressors such as CDKN2B and CDKN2A is commonly seen in all forms of human cancer (1) . Such inactivation of tumor suppressor genes can result from deletions, point mutations as well as reversible epigenetic events such as promoter hypermethylation (3, 4) . Tumor suppressor genes are frequently silenced by CpG island methylation in a number of cancers, including hematologic malignancies and solid tumors (5, 6) .
CDKN2B and CDKN2A specifically inhibit cyclindependent kinases CDK4 and CDK6. Their expression is induced by transforming growth factor TGFß. The CDKN2B and CDKN2A genes have been reported to be frequently methylated in hematological malignancies (5) and these cells are thought to evade TGFß regulation via this hypermethylation event.
Arsenic trioxide (As 2 O 3 ) has recently been found to be effective in the treatment of malignant hematopoietic diseases through induction of apoptosis and inhibition of cellular proliferation (7, 8) . It has been used to treat acute promyelocytic leukemia and multiple myeloma with good results, but showed equivocal results in a phase II trial for metastatic colon cancer (9) . It did not produce complete remission in renal cell carcinoma, metastatic melanoma or germ cell malignancies reflecting possible differences in pathogenesis, mechanism of genetic abnormalities and mechanism of tumor response to arsenic between solid tumors and hematological tumors (9) . Arsenic trioxide has been reported to utilize S-adenosyl methionine (SAM) (8, 10) , an essential co-factor of DNMTs (11) , in order to bring about DNA hypomethylation. As 2 O 3 may therefore play a role in the regulation of tumor suppressor genes by interfering with DNA methylation patterns.
We explored the status of CDKN2B and CDKN2A promoter hypermethylation in As 2 O 3 -treated human hematological malignancy cells, Molt4, U937, MUTZ-1, U266 and CA46. We also explored the possibility of manipulating the expression of the CDKN2B and CDKN2A genes in these cells by As 2 O 3 -mediated demethylation of CpG islands in the CDKN2B and CDKN2A promoters. Finally, we investigated the levels of DNA methyl transferases DNMT1, DNMT3a and DNMT3b in untreated and As 2 O 3 -treated cells to determine the mechanism of gene regulation by As 2 O 3 -mediated hypomethylation in these cells.
Materials and methods
Cell lines and reagents. Molt4 (an acute lymphoblastic leukemia cell line), U937 (an acute myelocytic leukemia cell line), MUTZ-1 (a myelodysplastic syndromes (MDS) cell line), U266 (a multiple myeloma cell line) and CA46 (a malignant lymphoma cell line) were obtained from the Wuhan Cell Bank (Wuhan, China). Cells were routinely cultured in RPMI-1640 (Gibco) supplemented with 10% heat-inactivated FBS (Shijiqing, Biosciences, Hangzhou, China) and incubated at 37˚C with 5% CO 2 in a humidified atmosphere. As 2 O 3 (Sigma, St. Louis, MO, USA) was dissolved in a small amount of 1.0 mol/l NaOH, then diluted to 10 mmol/l with phosphatebuffered saline (PBS) as stock solution. Cells (1x10 5 /ml) were treated with 0.5, 1.0 and 2.0 μmol/l of As 2 O 3 . In addition to untreated cells, normal human bone marrow cells from spina iliaca posterior superior were used as a control.
Bisulfite modification and nested-methylation specific polymerase chain reaction (n-MSP). Genomic DNA was extracted from Molt4, U937, MUTZ-1, U266 and CA46 cell lines using a DNeasy Tissue kit (Qiagen, Valencia, CA). DNA was modified using sodium bisulfite as previously described (12) . Bisulfite treatment of DNA converts unmethylated cytosine residues into uracil, but methylated cytosine residues remain unmodified (12) . Briefly, 2 μg of genomic DNA was denatured in 0.2 N NaOH at 37˚C for 10 min and incubated with 3 M sodium bisulfite at 50˚C for 15 h. The DNA was then purified using the Wizard DNA Clean-Up System (Promega, Madison, WI, USA), and desulfonated in 0.3 N NaOH at 25˚C for 5 min. DNA was precipitated with ammonium acetate and ethanol, washed with 70% ethanol, and resuspended in 20 μl H 2 O.
Primer sequences used to amplify methylated (M-MSP) and unmethylated (U-MSP) promoters of CDKN2B and CDKN2A are shown in Table I . Polymerase chain reaction Table I . Primer sequence, length and annealing temperature of n-MSP and RT-PCR. DNA sequence analysis of methylated CDKN2B and CDKN2A genes. The MSP PCR product of the CDKN2B and CDKN2A genes were recovered by using gel recovering kit, cloned in the PMD-18-T vector (Takara, Ltd.) and sequenced by BioAsia, Ltd.
Reverse transcriptase-polymerase chain reaction (RT-PCR).
Total RNA was extracted from 2-5x10 6 cells using TRIzol (Life Technologies, USA) according to the manufacturer's recommendations. Reverse transcription was performed using 2 μg total RNA, 500 ng of oligodT primers, 15 U of AMV reverse transcriptase, 20 U of RNasin (Promega) and 0.5 mM dNTPs in a final volume of 20 μl. The reaction was incubated at 42˚C for 60 min. The cDNA product was amplified by PCR in a final volume of 50 μl containing 3 μl of cDNA, 5 μl of 10X PCR buffer, 1 U Taq polymerase (Promega), 0.2 mM/ dNTP and 25 pmol of each primer. Thirty-five cycles of PCR were performed in a PE 2400 (Perkin-Elmer, USA) as follows: 94˚C, 30 sec; annealing temperature, 40 sec; 72˚C, 40 sec and the PCR product was analyzed on a 2% agarose gel. ß-actin was used as a positive control. Primer sequences and the amplified fragment sizes are listed in Table I .
Immunoblotting. The cells in each group were collected by centrifugation 72 h after treatment with As 2 O 3 , the supernatant were removed, then the precipitation were washed twice with PBS. After removing the supernatant, the cells were lysed with 100 μl lysis buffer and 1 μl protease inhibitor per 1x10 6 cells. The cells were fully dispersed and the tubes were slanted for 30 min at 4˚C, then they were centrifuged at 10000 rpm for 10 min at 4˚C and conserved at -20 or -80˚C for further analysis. The protein content were measured by Bradford method (Coomassie brilliant blue method). Total protein (30 μg) in each treatment group were loaded on 8% SDS-PAGE and transferred electrophoretically onto a nitrocellulose membrane. The nitrocellulose membrane were rinsed with Double-distilled water several times, protein wells and molecular weight standards were marked with a soft pencil. The membranes were blocked in 10X blocking buffer (10 ml PBS containing 1 g non-fat dry milk) for 2 h, and then incubated in a wet box at 4˚C for 36 h with mouse anti-human monoclonal antibody (diluted 1:750). After washing with PBS, the membranes were incubated in a shaker incubater with horseradish peroxidase labeled goat anti-mouse IgG (diluted 1:3000) at room temperature for 2 h. Immunocomplexes were visualized using the ECL Western blotting detection system according to the manufacturer's protocol (Amersham Biosciences, UK). We used the mouse monoclonal h-actin (Sigma) antibody as a loading control for Western blots at dilution of 1:1000.
DNMT enzyme activity assay. DNMT enzyme activity was assayed in nuclear extracts from untreated cells and cells treated with As 2 O 3 . Nuclear extracts were prepared as described above and 5 μg protein lysate was added to 200 μl of an assay mixture consisting of 20 mmol/l Tris-HCl, pH 7.4, 5 mmol/l EDTA, 25% glycerol, 0.5% Triton X-100, 1 mmol/l dithiothreitol, 0.2 mmol/l phenylmethylsulfonyl fluoride, 5 μCi of S-adenosyl-l-(methyl-3H)methionine (12 Ci/mmol), 4 μg of poly(dI-dC) and 200 μg/ml bovine serum albumin and incubated at 37˚C for 2 h. Reactions were subjected to 10% trichloroacetic acid precipitation and filtration through GF/C filters (Whatman, Ltd., Maidstone, UK). The precipitate was dried and then washed with 10% trichloroacetic acid (10%) and 70% ethanol. Filters were placed in scintillation mixture, and DNMT activity was determined by scintillation counting (Tricarb 2500TR, Packard, Meriden, USA). All assays were performed in triplicate. Background levels were determined in the absence of template DNA.
Statistical analysis. Normally distributed continuous variables were compared by one-way analysis of variance (ANOVA). When a significant difference between groups was apparent, multiple comparisons of means were performed using the Bonferroni procedure with type-I error adjustment. Data are presented as means ± SD. All statistical assessments were two-sided and evaluated at the 0.05 level of significant difference. Statistical analyses were performed using SPSS 15.0 statistics software (SPSS Inc., Chicago, IL).
Results
CpG methylation of CDKN2B or CDKN2A in Molt4, MUTZ-1, U937, U266 and CA46 cell lines. The methylation status of CpG islands of CDKN2B and CDKN2A genes was examined in Molt4, U937, MUTZ-1, U266 and CA46 cell lines. We demonstrated that the CDKN2B promoter was hypermethylated in Molt4 and MUTZ-1 cell lines while the CDKN2A was hypermethylated in U937, U266 and CA46 cell lines (Figs. 1 and 2).
As 2 O 3 -induced demethylation of CpG islands of CDKN2B or CDKN2A in Molt4, MUTZ-1, U937, U266 and CA46 cell lines.
The CDKN2B and CDKN2A genes were either partially or completely demethylated in Molt4, MUTZ-1, U937, U266 and CA46 cell lines after treatment with 0.5, 1.0 or 2.0 μmol/l As 2 O 3 for 72 h. We showed a significant decrease in the methylation specific bands of the CDKN2B and the CDKN2A genes in cells treated with 2 μmol/l of As 2 O 3 for 72 h. In contrast, there was an increase in the non-methylation specific bands of these genes in cells treated with 2 μmol/l of As 2 O 3 for 72 h (Figs. 3-7) . As 2 O 3 -mediated changes in the methylation patterns of CpG islands in the CDKN2B and CDKN2A genes were examined by DNA sequence analysis. We showed that DNA sulfuration in 2.0 μmol/l As 2 O 3 -treated Molt4 cells resulted in conversion of all cytosines in the CpG dinucleotides of the CDKN2B gene to thymidines. Untreated cells showed no change in these cytosine residues (Fig. 8 ). These data confirm that As 2 O 3 treatment resulted in demethylation of the hypermethylated CpG islands of the CDKN2B ONCOLOGY REPORTS 24: 335-343, 2010 gene in Molt4 cells. We also demonstrated (Fig. 9 ) that DNA sulfuration in 2.0 μmol/l As 2 O 3 -treated U937 cells resulted in conversion of all cytosines in CpG dinucleotides of the CDKN2A gene to thymidines. Untreated cells showed no change in these cytosine residues. These data confirm that As 2 O 3 treatment resulted in demethylation of the hypermethylated CpG islands of the CDKN2A gene in U937 cells.
As 2 O 3 -induced reactivation of CDKN2B or CDKN2A mRNA expression. We showed (Fig. 10A and B ) that Molt4 and U937 cells treated with different concentrations (0, 0.5, 1 and 2 μmol/l) of As 2 O 3 for 72 h showed alterations in their CDKN2B and CDKN2A mRNA levels. CDKN2B expression was silenced in untreated Molt4 cells while CDKN2A expression was silenced in untreated U937 cells. We showed ( Fig. 10C and D) a dose-dependent increase in CDKN2B or CDKN2A expression in As 2 O 3 -treated Molt4 and U937 cells when compared with untreated cells (P<0.001). These results suggest the possibility of As 2 O 3 -mediated reactivation of methylation-silenced CDKN2B or CDKN2A genes in different hematological malignant cell lines.
Western blot analysis of CDKN2B or CDKN2A. We used
Western blot analysis to demonstrate that CDKN2B or CDKN2A protein levels were increased in Molt4 and U937 cell lines treated with 0.5, 1 and 2 μmol/l of As 2 O 3 for 72 h ( Fig. 11A and B) , Untreated cells showed undetectable CDKN2B and CDKN2A expression. These data indicate that As 2 O 3 was able to restore partially or fully restore the expression levels of the CDKN2B or CDKN2A genes.
As 2 O 3 inhibits DNMT enzyme activity and DNMTs mRNA expression.
In order to investigate the mechanism of As 2 O 3 -induced DNA demethylation, we measured DNMT enzyme activity and DNMT mRNA levels in As 2 O 3 -treated cells. Using nuclear extracts from untreated and As 2 O 3 -treated cells as the source of DNMT and polydeoxyinosine-deoxycytosine as the substrate, we showed that As 2 O 3 inhibited DNMT activity in U266 cells in a dose-dependent manner (Fig. 12A) . We also showed a dose-dependent inhibition of DNMT1, DNMT3a and DNMT3b mRNA levels in As 2 O 3 -treated cells (P<0.001). DNMT1 mRNA levels were 8.7-fold higher in untreated U266 cells when compared with the normal control group (P<0.001; Fig. 12B ). DNMT3a mRNA levels were 6.5-fold higher in untreated U266 cells when compared with the normal control group (P<0.001; Fig. 12C ), while the mRNA expression of DNMT3b in untreated U266 cells was 4.9-fold higher when compared with the normal control group (P<0.001; Fig. 12D ). There was a dosedependent inhibition of DNMT1, DNMT3a and DNMT3b mRNA levels in As 2 O 3 -treated cells (P<0.001).
Discussion
CDKN2B and CDKN2A genes are important negative regulators of the cell cycle and bring about cell cycle arrest at G1 by interfere with the binding of CDKs 4/6, with Cyclin D and inhibiting phosphorylation of Rb (13) . CDKN2B and CDKN2A are thought to be tumor suppressors whose loss of function in tumors results in aberrant phosphorylation of retinoblastoma and accelerated cell growth (14) . Aberrant methylation of CpG islands (extending from the promoter region of these genes to exon 1) is an important mechanism by which the CDKN2A and the CDKN2B genes are transcriptionally inactivated (15) and this phenomenon has been reported in a number of human cancers (13) (14) (15) (16) (17) .
In this study, we demonstrated that the promoter of the CDKN2B gene was hypermethylated in Molt4 and MUTZ-1 cells and the promoter of the CDKN2A gene was hypermethylated in U937, U266 and CA46 cells. We also demon- strated undetectable mRNA levels in Molt4 and MUTZ-1 cells where the CDKN2B promoter was hypermethylated and undetectable CDKN2A mRNA levels in U937, UA266 and CA46 cells where the CDKN2A promoter was hypermethylated.
As 2 O 3 is known to be effective in the treatment of promyelocytic leukemia by efficiently inducing apoptosis and inhibiting cell proliferation (18, 19) . Although arsenic is known to be carcinogenic in humans, the mechanism of carcinogenicity remains unclear. Inorganic arsenic is detoxified in mammals via enzymatic conversion to monomethylated and dimethylated arsenic (20) in a reaction requiring SAM as a methyl donor and a methyltransferase enzyme such as Cyt19 (21) . Since SAM is also an essential cofactor for a variety of DNMTs, arsenic exposure induces SAM depletion (8) along with increased levels of S-adenosyl homocysteine (SAH) which is known to be an effective inhibitor of DNMT activity.
We demonstrated that low concentrations of As 2 O 3 induced demethylation of CpG islands in the promoters of the CDKN2B and CDKN2A genes in the Molt4, MUTZ-1, U937, U266 and CA46 cell lines. Demethylation of the CDKN2B and the CDKN2A genes caused an increase in their mRNA expression levels to levels comparable with those of the normal control group. This is an important finding suggesting that manipulation of methylation patterns can result in changes in the expression levels of tumor suppressor genes, which could have important clinical applications.
We previously studied p16 promoter methylation in a group of 82 adult leukemia patients and demonstrated that the p16 promoter was methylated in 39% of the patients. None of the control patients showed p16 promoter methylation (22) . We also showed that the p16 gene was demethylated and activated in As 2 O 3 -treated U266 cells, along with a concomitant growth arrest of these cells at the G1 phase (23) . We also showed p15 gene methylation in different malignant cell lines (24) . Our current study extends these findings by expanding the repertoire of hematological malignant cell lines to correlate with the results of our previous clinical study (22) . We plan to carry out flow cytometry to investigate cell cycle events in untreated and As 2 O 3 -treated cells in this study in order to determine the effects of CDKN2A and CDKN2B reactivation in all these cell lines. It could be informative to investigate the differential CDK inhibitor silencing and reactivation in different cell lines; why methylation of p15 gene occurs in certain tumor cell line, but some cell lines is occurred on p16 gene which is not explicit at present, further research is required.
Overexpression of DNMT1 and DNMT3a genes was previously reported to be an early event in hepatocarcinogenesis (25) and increased DNMT1 protein levels were reported to be a poor prognostic marker in HCC (26) . Previous research showed that As 2 O 3 suppressed DNMT1 mRNA levels specifically in HepG2 cells, while the expression of DNMT3a and DNMT3b remained unchanged (27) . However, our results showed that, in addition to inhibiting DNMT activity, As 2 O 3 also significantly down-regulated DNMT1, DNMT3a and DNMT3b mRNA levels in a dose-dependent manner in human hematological malignancies. We suggest that inhibition of DNMT activity is correlated with As 2 O 3 -mediated demethylation of CpG islands. Our future goals include an investigation of the mechanism of the As 2 O 3 -mediated transcriptional inhibition of DNMTs.
We recognize that the results presented in this study only pertain to in vitro cell culture systems and expect to confirm these results using in vivo studies as well as appropriate retrospective studies with patient samples.
In summary, we showed that low concentrations of As 2 O 3 induced demethylation of the CpG islands in the CDKN2B and CDKN2A gene promoters, with a consequent reactivation of these silenced genes in human hematologic malignancies. This As 2 O 3 -induced demethylation is correlated with DNMT inhibition. Although As 2 O 3 is known to be effective in the treatment of leukemias, especially acute promyelocytic leukemia, it has not been extensively used in the treatment of other human hematologic malignancies. Our data suggest that As 2 O 3 works in a wide variety of hematological malignant cell lines and restores the expression of tumor suppressor genes via inhibition of DNMT mRNA levels, DNMT activity and hypomethylation of CpG islands in the tumor suppressor genes.
